More than 70% of people without diabetes who receive a glucagon-like peptide-1 (GLP-1) agonist to lower weight eventually stop taking it within two years, according to Prime Therapeutics research presented at the AMCP Nexus 2024 annual meeting, in Las Vegas.
The investigators said this real-world evidence of a drop in persistence suggests that employers and pharmacy benefit managers (PBMs) should stratify by likelihood of adherence who receives GLP-1 agonists rather than offering